Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual obesity medicine practice with board-certified physicians, dietitians, and coaches; treats obesity as a chronic disease using GLP-1 medications with individualized behavioral plans.
Form Health is a virtual obesity medicine practice that delivers medically supervised weight loss care through a team-based model pairing board-certified obesity medicine physicians with registered dietitians and health coaches, all accessible through a telehealth platform. The practice treats obesity as a complex chronic disease and develops individualized treatment plans that may include anti-obesity medications — including GLP-1 receptor agonists like semaglutide and tirzepatide — alongside nutritional counseling, behavioral health support, and physical activity guidance based on each patient's medical history, comorbidities, and treatment goals. This multidisciplinary approach mirrors the clinical model of a hospital-based obesity medicine program delivered through a scalable virtual format.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.